Cargando…

Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes

Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term ou...

Descripción completa

Detalles Bibliográficos
Autores principales: Martínez, María José, Rueda, Ferran, Labata, Carlos, Oliveras, Teresa, Montero, Santiago, Ferrer, Marc, El Ouaddi, Nabil, Serra, Jordi, Lupón, Josep, Bayés-Genís, Antoni, García-García, Cosme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224589/
https://www.ncbi.nlm.nih.gov/pubmed/35743628
http://dx.doi.org/10.3390/jcm11123558
_version_ 1784733404719218688
author Martínez, María José
Rueda, Ferran
Labata, Carlos
Oliveras, Teresa
Montero, Santiago
Ferrer, Marc
El Ouaddi, Nabil
Serra, Jordi
Lupón, Josep
Bayés-Genís, Antoni
García-García, Cosme
author_facet Martínez, María José
Rueda, Ferran
Labata, Carlos
Oliveras, Teresa
Montero, Santiago
Ferrer, Marc
El Ouaddi, Nabil
Serra, Jordi
Lupón, Josep
Bayés-Genís, Antoni
García-García, Cosme
author_sort Martínez, María José
collection PubMed
description Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%; p = 0.004), even after multivariable adjustment (HR 1.91; 95% CI 1.16–3.14), but no differences in mortality were observed at 3 years. In conclusion, the 30-day case-fatality is higher in STEMI-CS, but the long-term outcome is similar in both groups.
format Online
Article
Text
id pubmed-9224589
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92245892022-06-24 Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes Martínez, María José Rueda, Ferran Labata, Carlos Oliveras, Teresa Montero, Santiago Ferrer, Marc El Ouaddi, Nabil Serra, Jordi Lupón, Josep Bayés-Genís, Antoni García-García, Cosme J Clin Med Article Cardiogenic shock (CS) is a severe complication of acute myocardial infarction (AMI). In AMI-CS, the ST segment deviation on ECG may be elevated (STEMI-CS) or non-elevated (NSTEMI-CS), which may influence prognosis. Our aim was to analyze the clinical profile, acute-phase prognosis, and long-term outcomes of CS relative to the ST pattern on admission. In a prospective registry of 4647 AMI patients admitted to the intensive cardiac care unit of a university hospital between 2010 and 2019, we compared the clinical characteristics, 30-days case fatality, and long-term outcomes of AMI-CS, based on the presence of ST-segment deviation. AMI-CS developed in 239 (5.1%) patients (26.4% women): 190 (79.5%) STEMI-CS and 49 (20.5%) NSTEMI-CS. The mean age was 69.7 years. The STEMI-CS patients had larger infarcts and more mechanical complications than the NSTEMI-CS patients. The NSTEMI-CS patients had a greater prevalence of hypertension, diabetes, peripheral vascular disease, previous cardiovascular comorbidities, three-vessel disease, and left main disease than the STEMI-CS patients. The STEMI-CS patients had higher 30-day mortality than the NSTEMI-CS (59.5% vs. 36.7%; p = 0.004), even after multivariable adjustment (HR 1.91; 95% CI 1.16–3.14), but no differences in mortality were observed at 3 years. In conclusion, the 30-day case-fatality is higher in STEMI-CS, but the long-term outcome is similar in both groups. MDPI 2022-06-20 /pmc/articles/PMC9224589/ /pubmed/35743628 http://dx.doi.org/10.3390/jcm11123558 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Martínez, María José
Rueda, Ferran
Labata, Carlos
Oliveras, Teresa
Montero, Santiago
Ferrer, Marc
El Ouaddi, Nabil
Serra, Jordi
Lupón, Josep
Bayés-Genís, Antoni
García-García, Cosme
Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
title Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
title_full Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
title_fullStr Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
title_full_unstemmed Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
title_short Non-STEMI vs. STEMI Cardiogenic Shock: Clinical Profile and Long-Term Outcomes
title_sort non-stemi vs. stemi cardiogenic shock: clinical profile and long-term outcomes
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224589/
https://www.ncbi.nlm.nih.gov/pubmed/35743628
http://dx.doi.org/10.3390/jcm11123558
work_keys_str_mv AT martinezmariajose nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT ruedaferran nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT labatacarlos nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT oliverasteresa nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT monterosantiago nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT ferrermarc nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT elouaddinabil nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT serrajordi nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT luponjosep nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT bayesgenisantoni nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes
AT garciagarciacosme nonstemivsstemicardiogenicshockclinicalprofileandlongtermoutcomes